Celldex Therapeutics reported $663.74M in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
AbbVie USD 37.48B 3.81B Sep/2026
Agenus USD 78.81M 16.47M Jun/2026
Amgen USD 34.36B 598M Sep/2026
Bristol-Myers Squibb USD 29.77B 1.19B Sep/2026
Celldex Therapeutics USD 663.74M 61.2M Sep/2026
Glaxosmithkline GBP 17.9B 134M Sep/2026
Nektar Therapeutics USD 589.04M 322.77M Mar/2026
Northwest Biotherapeutics USD 6.2M 996K Mar/2026
Pfizer USD 45.01B 3.65B Sep/2026
Rigel Pharmaceuticals USD 214.93M 39.53M Sep/2025
Roche Holding CHF 35.44B 3.29B Jun/2026